Lenvatinib: tested in a combination
307 studies: another drug in the study is under test too. Page 1 of 4. Open to participants first (149), then studies with results posted, then the rest; newest registration first within each.
- Serplulimab, DOS and Lenvatinib Combine With PIPAC in the Oligometastatic Peritoneal Metastasis of Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07902648Phase 2Report a problem
- Safety and Efficacy of Gemcitabine, Toripalimab and Dose- Modified Lenvatinib in Elderly Patients With Advanced Biliary Tract Cancer Intolerant to Conventional ChemotherapyNot yet recruitingNCT07897565Phase 2Report a problem
- Gematinib Combined With Lenvatinib for the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With MET Protein Overexpression: A Prospective, Multicenter, Phase II Clinical StudyNot yet recruitingNCT07894367Phase 2Report a problem
- Lenvatinib Plus Bevacizumab and PD-1 Inhibition Versus Bevacizumab Plus PD-1 Inhibition After Progression on Bevacizumab Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Prospective, Randomized, Two-Cohort, Phase II StudyNot yet recruitingNCT07870772Phase 2Report a problem
- Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective TrialRecruitingNCT07847359Phase 2Report a problem
- A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in Patients With Metastatic Non-small Cell Cancer With a RET Gene TranslocationRecruitingNCT07809256Phase 3Report a problem
- Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCCRecruitingNCT07801287Phase 2Report a problem
- A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular InvasionNot yet recruitingNCT07790419Phase 4Report a problem
- Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor ThrombusRecruitingNCT07776080Phase 2Report a problem
- A Prospective, Single-Arm, Multicenter Clinical Study of High-Risk Localized and Locally Advanced Renal Clear Cell CarcinomaNot yet recruitingNCT07741617Phase 2Report a problem
- Iparomlimab and Tuvonralimab (QL1706) Plus Lenvatinib and Chemotherapy for Extrapulmonary Neuroendocrine CarcinomaNot yet recruitingNCT07738159Phase 2Report a problem
- Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical TrialNot yet recruitingNCT07715565Phase 2Report a problem
- HAIC + DEB-TACE + Toripalimab + Lenvatinib for Unresectable Intrahepatic CholangiocarcinomaNot yet recruitingNCT07685535Phase 2Report a problem
- Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell CancerNot yet recruitingNCT07680088Phase 2Report a problem
- A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.RecruitingNCT07679399Phase 2Report a problem
- Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract CancerRecruitingNCT07636798Phase 1/2Report a problem
- EVERolimus and LenvAtinib Versus Everolimus for Bone SarcomaNot yet recruitingNCT07619950Phase 2Report a problem
- Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy MaintenanceRecruitingNCT07594015Phase 2Report a problem
- Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell CarcinomaNot yet recruitingNCT07593040Phase 2Report a problem
- Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell CarcinomaRecruitingNCT07571551Phase 2Report a problem
- Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib.Enrolling by invitationNCT07550972Phase 2Report a problem
- Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract CancerRecruitingNCT07530445Phase 2Report a problem
- Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow MarginNot yet recruitingNCT07518706Phase 2Report a problem
- Efficacy and Safety Comparison Between Intensified Therapy and Conversion Therapy For Advanced HCC After Failure of First-lineRecruitingNCT07501351Phase 2Report a problem
- Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE)Not yet recruitingNCT07495579Phase 2Report a problem
- Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor ThrombusRecruitingNCT07483359Phase 2Report a problem
- A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular CarcinomaRecruitingNCT07482059Phase 1/2Report a problem
- Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCCNot yet recruitingNCT07480382Not applicableReport a problem
- A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of RecurrenceRecruitingNCT07475026Phase 3Report a problem
- Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatmentNot yet recruitingNCT07460206Phase 2Report a problem
- A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICCNot yet recruitingNCT07432568Phase 2Report a problem
- Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 AmplificationRecruitingNCT07417501Phase 2Report a problem
- Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCCRecruitingNCT07389629Phase 2Report a problem
- QL1706 Plus Lenvatinib in Previously Treated Penile CancerRecruitingNCT07384416Phase 2Report a problem
- Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix CancerNot yet recruitingNCT07368985Phase 2Report a problem
- Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction AdenocarcinomaEnrolling by invitationNCT07356466Early Phase 1Report a problem
- A Prospective, Single-Arm, Phase II Clinical Study of Neoadjuvant Therapy With Pucotenlimab, Lenvatinib, and Temozolomide for Resectable Head and Neck Mucosal Melanoma (PLT-NAT-HNMM-II)Not yet recruitingNCT07353073Phase 2Report a problem
- TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal HypertensionNot yet recruitingNCT07350070Phase 2Report a problem
- Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01RecruitingNCT07290894Phase 2Report a problem
- Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and InterventionRecruitingNCT07282184Phase 1/2Report a problem
- Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic TherapyNot yet recruitingNCT07277972Phase 2Report a problem
- A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract CancerNot yet recruitingNCT07269158Phase 1/2Report a problem
- Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder CancerNot yet recruitingNCT07263360Phase 2Report a problem
- A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver SpreadNot yet recruitingNCT07256223Phase 2Report a problem
- Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepatoblastoma in ChildrenRecruitingNCT07188311Not applicableReport a problem
- Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TBNot yet recruitingNCT07160361Phase 4Report a problem
- Immunotherapy Combined With Anti-angiogenic Therapy and Chemotherapy for Potentially Resectable MSI-H, dMMR Locally Advanced Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07151209Phase 2Report a problem
- A Phase II Single-Arm Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Lenvatinib and TACE for Advanced Hepatocellular CarcinomaNot yet recruitingNCT07150377Phase 2Report a problem
- A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular CarcinomaNot yet recruitingNCT07131501Phase 2Report a problem
- QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic CancerRecruitingNCT07110064Phase 2Report a problem
- A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination RegimenNot yet recruitingNCT07099794Phase 2Report a problem
- Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular CarcinomaRecruitingNCT07099274Phase 2Report a problem
- Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver ResectionNot yet recruitingNCT07077798Not applicableReport a problem
- Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic CholangiocarcinomaRecruitingNCT07070700Phase 2Report a problem
- Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular CarcinomaRecruitingNCT07014150Phase 2Report a problem
- Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort StudyNot yet recruitingNCT07010393Phase 4Report a problem
- Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)Enrolling by invitationNCT06963060Phase 2Report a problem
- Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCCRecruitingNCT06904014Phase 2Report a problem
- An Exploratory Clinical Study on Neoadjuvant Treatment of Hepatocellular Carcinoma with QL1706 Combined with LenvatinibNot yet recruitingNCT06884982Phase 2Report a problem
- Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01)RecruitingNCT06860477Phase 2Report a problem
- Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)RecruitingNCT06859684Phase 2Report a problem
- Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder CancerRecruitingNCT06852287Phase 2Report a problem
- HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast CancerNot yet recruitingNCT06849492Phase 2Report a problem
- Study of Sinibolimab Combined with Lenvatinib As Neoadjuvant Therapy for Locally Advanced Unresectable Differentiated Thyroid CarcinomaNot yet recruitingNCT06848920Phase 2Report a problem
- Comparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric CancerNot yet recruitingNCT06748508Phase 2Report a problem
- Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs TherapyNot yet recruitingNCT06746961Phase 1/2Report a problem
- TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular CarcinomaRecruitingNCT06740370Not applicableReport a problem
- Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment ExhaustionRecruitingNCT06739395Phase 2Report a problem
- Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma PatientsRecruitingNCT06673628Phase 2Report a problem
- Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial TreatmentRecruitingNCT06669572Phase 2Report a problem
- Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICCNot yet recruitingNCT06648525Phase 2Report a problem
- Cardenilimab Combined With Lenvatinib in Patients With Perioperative Resectable Clear Cell Renal Cell Carcinoma.Not yet recruitingNCT06574412Phase 2Report a problem
- Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular CarcinomaRecruitingNCT06470256Phase 1Report a problem
- Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract CarcinomaNot yet recruitingNCT06463548Not applicableReport a problem
- Precision Treatment of Unresectable HCC Guided by Multi-omics Deep Learning ModelsRecruitingNCT06463444Phase 1Report a problem
- Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular CarcinomaRecruitingNCT06406634Phase 2Report a problem
- HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract CancerNot yet recruitingNCT06389500Phase 2Report a problem
- Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer PatientsRecruitingNCT06383559Phase 2Report a problem
- Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid CancerRecruitingNCT06374602Phase 2Report a problem
- CARE1 Pragmatic Clinical TrialRecruitingNCT06364631Phase 3Report a problem
- HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCCRecruitingNCT06364007Phase 2Report a problem
- Using Chronobiology to Improve Lenvatinib EfficacyRecruitingNCT06321120Early Phase 1Report a problem
- Precision Adjuvant Therapy After Surgery for Hepatocellular CarcinomaRecruitingNCT06311929Phase 4Report a problem
- Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model.Not yet recruitingNCT06311916Phase 4Report a problem
- Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic CholangiocarcinomaRecruitingNCT06298968Phase 2Report a problem
- A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma PatientsRecruitingNCT06277024Not applicableReport a problem
- Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)RecruitingNCT06266338Phase 2Report a problem
- Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401)RecruitingNCT06261125Phase 2Report a problem
- Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial CancerRecruitingNCT06253494Phase 1/2Report a problem
- Lenvatinib Plus Toripalimab for Platinum-Resistant Recurrent Ovarian CancerRecruitingNCT06241105Phase 2Report a problem
- Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract CancerRecruitingNCT06230471Phase 2Report a problem
- Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular CarcinomaRecruitingNCT06215651Phase 2Report a problem
- HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL)Not yet recruitingNCT06210334Phase 2Report a problem
- Neoadjuvant Therapy of HAIC(GEMOX) Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence FactorsRecruitingNCT06208462Phase 2Report a problem
- A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid CancerRecruitingNCT06195228Phase 4Report a problem
- Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic CholangiocarcinomaRecruitingNCT06192797Phase 2Report a problem
- Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic CholangiocarcinomaRecruitingNCT06192784Phase 2Report a problem
- HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular CarcinomaRecruitingNCT06187961Phase 2Report a problem
- Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscoreRecruitingNCT06157996Phase 2Report a problem
- A Study of HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular CarcinomaNot yet recruitingNCT06143579Phase 2Report a problem